Continued strong growth in Q3

Continued strong growth in Q3
Press Release | Jul 05. 2016 06:11 GMT

Strong organic revenue growth of 13% in the first nine months of 2015/16: Food Cultures & Enzymes (13%), Health & Nutrition (2%) and Natural Colors (20%). EBIT before special items increased by 18% to EUR 189 million. In Q3, organic growth reached 12% and EBIT before special items increased by 11% to EUR 71 million.

EUR million Q3 2015/16 Q3 2014/15 Growth YTD 2015/16 YTD 2014/15 Growth
Revenue 249.8 228.1 10% 693.1 625.0 11%
EBIT before special items 71.0 63.8 11% 188.9 159.8 18%
Profit for the period 51.6 45.7 13% 127.9 111.0 15%
Free cash flow* 42.0 53.8 -22% 57.8 65.0 -11%
Organic growth 12% 7% 13% 9%
Gross margin 53.3% 52.4% 52.8% 51.4%
EBIT margin b.s.i. 28.4% 28.0% 27.2% 25.6%
ROIC excl. goodwill 36.0% 33.8%


CEO Cees de Jong says: “We continued to grow our business during Q3, with Food Cultures & Enzymes and Natural Colors showing strong organic revenue growth. Both Food Cultures & Enzymes and Natural Colors also delivered encouraging improvements in profitability. We experienced modest growth in Health & Nutrition, as the animal health business was negatively impacted by commodity prices for milk and meat remaining at extraordinarily low levels. Despite the current pressure on the agricultural sector, the long-term growth prospects for our animal health business remain very positive.”

“During the past three months, we have made good progress with integrating NPC, launched a second product for plant health with good first sales, and, within the human microbiome area, successfully completed a clinical study showing a positive physiological effect of the bacteria tested. Based on the results achieved, we have moved to the next stage in our clinical development plan. Finally, it is very encouraging to see a strong performance by our bioprotective solutions for dairy and other food categories.”


OUTLOOK FOR 2015/16

The outlook for 2015/16 is unchanged compared to the announcement of 7 April, 2016.

7 April, 2016

Organic revenue growth: 10-12%

Research & development expenditures incurred (% of revenue): Around 7%

EBIT margin before special items above 2014/15: above 2014/15

Free cash flow before acquisitions and divestments: above 2014/15

5 July, 2016

Organic revenue growth: 10-12%

Research & development expenditures incurred (% of revenue): Around 7%

EBIT margin before special items above 2014/15: above 2014/15

Free cash flow before acquisitions and divestments: above 2014/15


The Q3 2015/2016 report was released today, 5 July, 2016, and is available from here.


Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, cleaner labels and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable biotech company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.

Share this with: